European Migraine Webinar Series 2020 - Header Image

Webinar

25.03.2021 - 25.03.2021 Reducing the Burden of Migraine: Data from Patient-reported Outcomes

Migraine is the second most disabling condition globally and has an estimated prevalence of 14.7% in Europe.1,2 However, the current understanding of the burden of migraine is limited.3 In the My Migraine Voice survey, 85% of 11,266 participants reported at least one negative aspect of living with migraine.3 In order of decreasing prevalence, the negative aspects reported were feeling misunderstood by others (48%), feeling depressed (41%), having feelings related to hating their lives (39%), feeling helpless (39%), and feeling that migraine controls and dictates their lives (39%).3 The impact of migraine extends from an individual’s private life to their professional life, with an average of 4.6 working days missed due to migraine per month.3 Indeed, the estimated mean annual costs per person in Europe amount to €1,222 for migraine alone.4 

In this webinar, Professor Patricia Pozo-Rosich from the Vall d’Hebron University Hospital in Barcelona, Spain, discusses the impact of migraine and presents patient-reported outcomes data highlighting the role of anti-CGRP monoclonal antibodies in reducing disability associated with migraine and improving the quality of life among individuals with migraine. 

We look forward to welcoming you to this insightful event dedicated to reducing the burden of migraine.

Click here to register for the webinar. 

References
  1. GBD 2016 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-59.

  2. Stovner LJ, Andree C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain 2010;11:289-99.

  3. Martelletti P, Schwedt TJ, Lanteri-Minet M, et al. My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. J Headache Pain 2018;19:115.

  4. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703-11.